A carregar...
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
BACKGROUND: As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD but i...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3040135/ https://ncbi.nlm.nih.gov/pubmed/21272339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1465-9921-12-18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|